Hutchison Medipharma Limited
80
1
7
51
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.8%
7 terminated/withdrawn out of 80 trials
87.9%
+1.4% vs industry average
16%
13 trials in Phase 3/4
20%
10 of 51 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (80)
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Role: collaborator
Savolitinib vs. Sunitinib in MET-driven PRCC.
Role: collaborator
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Role: lead
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
Role: lead
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Role: lead
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Role: lead
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
Role: lead
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Role: lead
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Role: lead
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Role: lead
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
Role: collaborator
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
Role: lead
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Role: collaborator
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Role: lead
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
Role: lead
A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Role: lead
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Role: collaborator
A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
Role: lead
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
Role: lead
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Role: collaborator